Linvoseltamab Pivotal Data Presented at AACR Reinforce High

TARRYTOWN, N.Y., April 07, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the oral plenary session presentation of positive pivotal data from the Phase 1/2 LINKER-MM1 trial

Related Keywords

Tarrytown , New York , United States , San Diego , California , American , Vesna Tosic , Tammy Allen , Sundar Jagannath , Exchange Commission , Myeloma Center , Linkedin , Regeneron Genetics Center , American Association For Cancer Research , Nasdaq , Drug Administration , Regeneron Pharmaceuticals Inc , Clinical Development Program , European Medicines Agency , American Association , Cancer Research , Annual Meeting , Multiple Myeloma Center , Tisch Cancer Center , Mount Sinai , New York City , Linvoseltamab Phase , Clinical Development , Looking Statements , Regeneron Pharmaceuticals , Product Candidates , Region ,